Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLATINUM: Nibrozetone + Platinum Chemo in SCLC
NCT05566041Phase 3Active, not recruiting
- Sponsor
- EpicentRx
- Start
- Aug 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Nibrozetone in small cell lung cancer (SCLC), sponsored by EpicentRx. Started Aug 2022; status: active, not recruiting.
02
Drugs
Nibrozetone
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05566041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566041.